


Prevalence of peri-implant diseases – a critical review on the current evidence

Raluca COSGAREA^(a) 

Anton SCULEAN^(b) 

Jamil Avad SHIBLI^(c) 

Giovanni Edoardo SALVI^(b) 

^(a)University Iuliu Hatieganu, Department of Prosthetic Dentistry, Cluj-Napoca, Romania.

^(b)University of Bern, School of Dental Medicine, Department of Periodontology, Bern, Switzerland.

^(c)Universidade de Guarulhos – UnG, Dental Research Division, Department of Periodontology and Oral Implantology, São Paulo, SP, Brazil.

Declaration of Interests: The authors certify that they have no commercial or associative interest that represents a conflict of interest in connection with the manuscript.

Corresponding Author:

Raluca Cosgarea

E-mail: raluca.cosgarea@gmail.com

<https://doi.org/10.1590/1807-3107bor-2019.vol33.0063>

Submitted: June 11, 2019

Accepted for publication: June 13, 2019

Last revision: June 17, 2019

Abstract: The objective of this paper was to evaluate the current evidence reporting on the prevalence of peri-implantitis and to determine the influencing factors. An electronic search for articles published until February 2019 reporting on the prevalence of peri-implantitis was performed in MEDLINE. Included criteria were published in international peer-reviewed journals, written in English language, reported on the prevalence of peri-implantitis, included implants with a minimum follow-up of one year after functional loading and used a clear definition for peri-implantitis and/or peri-implant mucositis with a clear cutoff for bone level changes according to the case definitions of Sanz and Chapple and Berglundh et al. 2018. Included papers were analyzed for factors affecting the reported prevalences for peri-implantitis. Twenty-five papers were included in the present review and a wide range for the reported prevalence of peri-implantitis was seen. Case definitions for peri-implantitis with various thresholds for bone loss together with the type of reporting on patient- or implant-level were the most significant factors that lead to a large variety of the occurrence of the disease. Additionally, follow-up time and the evaluation in a certain “convenience” population may have influenced the prevalence values. In conclusion, it can be stated that a wide range for reporting the prevalence of peri-implantitis can be found and no real estimation of the global burden of the disease can be made. Applying accurate case definitions for peri-implantitis is the most important factor for reporting the prevalence and should be strictly followed in future reports.

Keywords: Dental Implants; Peri-Implantitis; Prevalence; Mucositis.

Introduction

In the past two decades, dental implants have become a widely accepted and implemented therapeutical method to replace missing teeth and support fixed and partially removable prostheses. High long-term survival rates have been reported both for systemically healthy (cumulative survival rates of 83.8% after 25 years, 96.1% after 10 years)^{1,2} as well as for medically compromised patients (i.e. oral cancer: cumulative survival rate after 20 years 90.8%).³ Despite the high survival rates and intensive periodontal and prosthetical maintenance over time, implant failures may occur.^{4,5,6} In the last decades, evidence on the presence of



peri-implant inflammations affecting both soft and hard tissues that may eventually lead to implant failure (loss) has substantially increased. These are seen as biological complications related to inflammatory conditions of the surrounding soft and bone tissues, which are induced by bacterial biofilm and are distinguished as peri-implant mucositis and peri-implantitis.^{7,8,9}

Peri-implantitis was firstly described in 1987 by Mombelli et al.¹⁰ as an infectious disease with many common features to periodontitis. Considering the multiple etiological factors and clinical characteristics, many definitions arose and, from the clinical perspective, no consensus for a clear definition for peri-implantitis was settled. Peri-implantitis was mainly defined as an inflammatory response of the peri-implant mucosa with marginal bone loss, while peri-implant mucositis resumed to soft-tissues inflammation.^{11,12} Discrepancies in case definitions and disease estimations on various convenience samples led to controversial reports on the prevalence of peri-implant diseases.^{13,14} The lack of clear clinical parameters in these definitions led to a large range in the reported prevalence/incidence of peri-implant diseases making thus difficult to estimate the real burden of these pathologies. Considering the definitions for incidence (“the number of new cases of a specific disease occurring during a certain period”) and prevalence of a disease (“the number of cases of a disease in existence at a certain time point”),¹⁵ the use of longitudinal studies has been proposed for assessing the incidence while that of cross-sectional studies for determining the prevalence of peri-implant diseases.¹¹ Nonetheless, in november 2017 in the World Workshop on Periodontology (WWP), the European Federation of Periodontology (EFP) and the American Academy of Periodontology (AAP) reached a consensus and set clear a definition with clear clinical cutoff points for peri-implant pathologies both for the day-to-day clinical practice as well as for epidemiological studies.^{16,17,18,19}

Therefore, the aim of the present review, was to critically analyze the available evidence for the

prevalence of peri-implantitis in the light of the current definition of peri-implant diseases.

Methodology

A literature search for articles published until February 2019 reporting on the prevalence and/or incidence of peri-implantitis and peri-implant mucositis was performed in MEDLINE via PubMed database. Included studies had to be: published in international peer-reviewed journals, written in English language, report on the prevalence and/or incidence of peri-implantitis and/or mucositis, include implants with a minimum follow-up of one year after functional loading and a clear definition for peri-implantitis and/or peri-implant mucositis with a clear cutoff for bone level changes ($\geq 2/\geq 3$ mm apical of the coronal part of the implant, in the absence of previous radiographic measurements, or bone loss beyond crestal bone level changes after initial bone remodeling after the first year of loading).^{9,16}

Results

The initial electronic search revealed 248 publications; after abstract screening of the abstracts based on the inclusion criteria, 35 papers were selected for full-paper analysis. Included studies can be found in Table. Most of the papers considered in the definition for peri-implantitis a cutoff for bone loss of 2mm or calculated the bone loss from a level of 2-3 implant threads. Applying strictly all recommended definition criteria for peri-implantitis of the WWP 2017 (BOP/SUP, pocket depths ≥ 6 mm, bone level ≥ 3 mm of the most coronal portion of the intraosseous part of the implant) no single study can be taken into consideration.¹⁶

Discussion

A wide range of prevalences for peri-implant biological complications has been reported in the literature so far. Reviews and meta-analyses from the past three years mention prevalences for peri-implant mucositis of 42.9%,¹³ of 29.48% (implant level) or 46.83% (patient-based);²⁰ for peri-implantitis

Table. Included studies reporting on the prevalence of peri-implant mucositis and peri-implantitis.

No.	Study	Country	Study type	Case definitions for mucositis	Prevalence of mucositis	Prevalence of Peri-implantitis (PI)	Possible associated risk factors (implant type/surface, keratinized mucosa, history of periodontitis, diabetes, smoking, prosthetics)
			Patients	Peri-implantitis			
			Setting: University/ private practice				
			Evaluation period				
1	Aguirre-Zorzano et al. 2015 ³⁷	Spain	Cross-sectional	Mucositis:	Patient level: 24.7%	Patient level: 15.1%	Stat. sign. association for plaque index, periodontitis and implant location with mucositis.
			Retrospective	BOP, clinical signs of inflammation, no BL (< 1.5 mm)			
			239 patients/786 implants	PI: BOP, clinical signs of inflammation, BL (≥ 1.5 mm)	Implant level: 12.8%	Implant level: 9.8%	Stat. sign. association for plaque index and implant location with PI.
			university 6–17y (mean 5.3 y) functional loading				
2	Canullo et al. 2016 ⁶³	Spain	Cross-sectional	Mucositis: n.r.		Patient level: 10.3%	Peri-implantitis implants showed higher % of plaque, of BOP, < 2mm attached gingiva, more cemented crowns, more bone-augmented sites.
			588 patients/1507 implants	PI: PD≥4mm, BOP/SUP, BL>3mm	n.r.	Implant level: 7.3%	
			university 5.1 y				
3	Cecchinato et al. 2014 ³¹	Italy	Cross-sectional	Mucositis: BOP, BL≤0.5 mm	Patient level: 65%	Patient level: 12% (within 10 y)	n.r.
			100 patients/ 291 implants analysed	PI: PD≥4mm, BOP, BL>0.5mm from > 1 year after loading	Implant level: 69.8%	Implant level: 5% (within 10 y)	
			Private practice ≥ 8 y (mean 10.7 y) functional loading				
4	Daubert et al. 2015 ³⁴	USA	Cross-sectional	Mucositis: BOP, gingival inflammation, no BL	Patient level: 48%	Patient level: 26%	Association betw. PI and diabetes and younger age at implant insertion, periodontal status at follow-up.
			96 patients/ 225 implants	PI: BOP/SUP, BL≥2mm after initial remodeling, PD≥4mm	Implant level: 33%	Implant level: 16%	No association with smoking
			university 9–15 y (mean 10.9 y)				

Continue

Continuation

5	Derks et al. 2016 ²⁴	Sweden	Cross-sectional Retrospective 588 patients/2277 implants university, private practice 9 years functional loading	Mucositis: BOP/SUP, no BL PI: BOP/SUP, BL (> 0.5 mm) Moderate/severe PI: BOP/SUP, >2mm BL	Patient level: 32% Implant level: 35.1%	Patient level: 45% BL: > 2 mm: 14.5% > 3 mm: 10.1% > 4 mm: 5.9% Implant level: 24.9% BL: > 2 mm: 8.0% > 3 mm: 4.3% > 4 mm: 2.3%	Stat. sign. higher OR for moderate/severe PI for history of periodontitis (4.1), ≥4 implants (15.1), in the mandibular region (2.0), distance between prosthetic restoration margin and initial crestal bone level ≤ 1.5mm (2.3), for general practitioners as provider for prosthetics (4.3), certain brands of implants: Astra Tech (3.6, mostly TiOblast surface), Nobel Biocare (3.8, mostly TiUnite surface), Straumann (1, all SLA surface), remaining implant brands (5.56).
6	Fransson et al. 2005, 2008 ^{64,65}	Sweden	cross-sectional 662 patients /3413 implants- 82 patients with clinical assessment /482 implants university 5–20 y (mean 9.4y)	Mucositis: BOP, BL≤0.6mm from 1 year after loading PI: BOP, bone level ≥3 threads & BL≥0.6mm from 1 y after loading	Patient level: n.r. Implant level: > 90%	Patient level: 27.8% Implant level: 12.4%	Smokers had a higher number of affected implants than non-smokers. A higher proportion of peri-implant clinical pathology (SUP& PD≥6mm) in smokers than in non-smokers. Higher frequency of peri-implant clinical pathology (BOP, SUP, recession, PD≥6mm) at implants with progressive BL
7	Francetti et al. 2019 ⁵³	Italy	Cross-sectional 77 patients/384 implants Private clinic 14.6% (after 5 y)13.7y (mean 8y)	Mucositis: n.r. PI: BOP/SUP, BL>2mm	n.r.	Patient level: 12.7 % (after 5y) Implant level: 4.6% (after 5 y)	No sign. Risk factors: smoking (p=0.755), periodontitis (p=0.399)
8	French et al. 2019 ⁵⁴	Canada	Retrospective cohort study 2060 patients/4591 implants private practice 5 Mucositis+BL≥1 mm one y after installation10 y (mean 6.7y)	Mucositis: Implant mucosal Index (IMI) Strict criteria: ≥2 Relaxed criteria ≥1 PI: Mucositis + B L ≥ 1 mm one y after installation	Implant level: 38.6% (relaxed criteria) 14.2% (strict criteria)(6.7y)	Implant level: 4.7% (relaxed criteria) 3.6% (strict criteria)(6.7y)	Risk factors with effect on BL: autoimmune disease, heavy smoking, bisphosphonate therapy, implant location, diameter and design, and BL

Continue

Continuation

9	Katafuchi et al. 2018 ⁵⁵	USA	Cross-sectional 83 patients/168 implants mean 10.9 y	Mucositis: n.r. PI: BOP/SUO, BL \geq 2mm after initial remodeling, PD \geq 4mm	n.r.	Implant level: 16.7% bone level implant: 22.8% tissue level implants: 7.5% Patient level: 25.3% Bone level implants: 28.9% Tissue level implants: 14.8%	Emergence profile >30 degrees is a significant risk indicator for PI; convex profile additionally for bone-level implants.
10	Koldsland et al. 2010 & 2011 ^{32,66}	Norway	Cross-sectional 103 patients/374 implants University 1-16 y (mean 8.4y) functional loading	Mucositis: inflammation (bleeding, BOP, SUP), no BL PI: inflammation (bleeding, BOP, SUP), BL (\geq 2mm, or \geq 3mm)	Patient level: 39.4% Implant level: 27.3%	Patient level: 47.1% Implant level: 36.6%	n.r.
11	Konstantinidis et al. 2015 ³⁵	Germany	Cross-sectional 186 patients/ 597 implants university 1-16.5 y (mean 5.5y)	Mucositis: BOP, no BL (BL<2mm) PI: BOP, PD \geq 5 mm, B L > 2 mm	Patient level: 64.5% Implant level: 57.0%	Patient level: 12.9% Implant level: 6.2%	High plaque score (OR:1.36) was a risk indicator for mucositis, while soft- or hard-tissue augmentation had a protective effect. Loss of the last tooth in the dentition (OR:1.06) and location in the maxilla (OR:1.05) were risk factors for peri-implantitis.
12	Marrone et al. 2013 ⁵⁶	Belgium	Cross-sectional 103 patients/266 implants private practice & university 5-18 y (mean 8.5y)	Mucositis: PD \leq 5mm, BOP, BL \leq 2mm PI: PD>5mm, BOP, BL>2mm	Patient level: 31% Implant level: 38%	Patient level: 37% Implant level: 23%	Age over 65y (OR:1.39), active periodontitis (OR: 1.98), hepatitis (OR: 2.92) and edentulism (OR:5.56) were associated with peri-implantitis. Sign. correlation between peri-implantitis and rough implant surfaces and overdentures.
13	Meijer et al. 2014 ²⁵	Netherlands	Prospective cohort study 150 patients/ 275 implants (5 y), 240 implants (10 y) university 5 and 10 y functional loading	Mucositis: BOP/SUP, BL<2mm PI: BOP/SUP, BL \geq 2mm	Incidence: Patient level: 51.9% (5 y) 57.0% (10 y)	Incidence: Patient level: 16.9% (5 y) 29.7% (10 y)	n.r.

Continue

Continuation

14	Mir-Mari et al. 2012 ⁴⁸	Spain	Cross-sectional 245 patients/ 964 implants private practice 1–18 y (mean 6.3 y)	Mucositis: BOP, BL < 2 implant threads PI: BOP/SUP, BL ≥ 2 implant threads	Patient level: 38.8% Implant level: 21.6%	Patient level: 16.3% Implant level: 9.1%	n.r.
15	Monje et al. 2017 ⁶⁷	Spain	Cross-sectional 115 patients/ 206 implants Private practice 3–4.6 y (mean 3.9y)	Mucositis: BOP/SUP, swelling, BL < 2 mm PI: BOP/SUP, redness, BL > 2mm	n.r.	Patient level: RC (regular compliers 3-6m recall): 4.5% EC (erratic compliers: 7-12m recall): 26.3% NC (non-compliers, no recall): 14.3% Implant level: RC: 2.4% EC: 19% NC: 8.7%	Stat. sign. association (p=0.04) betw. compliance to maintenance therapy and peri-implantitis. Compliance was associated with 86% fewer conditions of peri-implantitis.
16	Papaspyridakos et al. 2018 ⁶⁸	USA	Cross-sectional 52 patients/457 rough implants university 1–12y (mean 5.2y)	Mucositis: n.r. PI: BL > 2mm after 1 st y of function/ > 0.2mm per y, BOP/SUP	Implant level: 31.5% (estim. 5 y) 63.0% (estim. 10y)	Implant level: 10% (estim. 5 y) 20% (estim 10 y)	High plaque index was associated stat. sign. with bone loss
17	Renvert et al. 2014 ⁵⁸	Sweden	Cross-sectional, retrospective 270 patients/n.r. University Mean 10.1 y functional loading	Mucositis: BOP/SUP, edema, BL < 2mm PI: PD ≥ 4mm, BOP/SUP, BL > 2mm	Patient level: 36.3% -Peri-implant health/ mucositis	Patient level: 63.7% (172 patients)	OR of having peri-implantitis was stat. sign for history of cardio-vascular disease (8.7) and of periodontitis (4.5). No association betw. PI and smoking or gender.
18	Renvert et al. 2018 ⁴⁶	Sweden	Cross-sectional 218 patients (9–14 y) 86 patients (20–26y) university	Mucositis: BOP/SUP, no BL PI: BOP/SUP, BL (3 imp. threads)	Implant level: 82.6% (10y) 91.1% (20y)	Implant level: 4.8% (10y) 10.8% (20y)	Patients with ≥ 3 implants at 10 years had a higher risk for PI at 20 y. No predictive value for PI at 20y for radiographic evidence of periodontitis, mucositis, smoking.

Continue

Continuation

19	Rinke et al. 2011 ⁶⁹	Germany	Cross-sectional 89 patients/n.r. private practice 2–11 y (mean 5.7y)	Mucositis: PD \geq 4 mm, BOP PI: PD \geq 5 mm, BOP/SUP, BL	Patient level: 44.9%	Patient level: 11.2%	Significant association betw. mucositis and smoking (OR: 3.77). Significant association betw. peri-implantitis and smoking (OR:31.58) and compliance (OR:0.09).
20	Rokn et al. 2016 ³⁶	Iran	Cross-sectional 134 patients/478 implants (55% tissue level) university 1–11 y (mean 4.4 y)	Mucositis: BOP/SUP, BL \leq 2 mm PI: BOP/SUP, BL > 2mm	Patient level: 48.5%	Patient level: 20%	Smoking (OR: 2.57) and lack of keratinized mucosa (OR: 3.89) were associated with PI.
21	Roos-Jansaker et al. 2006 ⁴⁵	Sweden	Cross-sectional 216 patients/ 999 implants analysed university 9–14y (mean 11y)	Mucositis: PD \geq 4 mm, BOP, BL <1 thread PI: BOP/SUP, BL \geq 1.8 mm from 1 y after loading	Patient level: 48%	Patient level: 16%	n.r.
22	Schwarz et al. 2017 ⁴⁷	Germany	Cross-sectional 238 patients/ 512 implants university 1–6.7y (mean 2.2 y)	Mucositis: BOP, no changes at bone level compared to baseline PI: BOP/SUP, changes at bone level compared to baseline	Patient level: 41.6%	Patient level: 13.9%	Plaque (OR: 8.4) and male gender (OR: 2.0) were associated with mucositis.
23	Simonis et al. 2010 ⁵¹	France	Retrospective cohort study 55 patient/131 implants university 10–16y	Mucositis: n.r. PI: PD \geq 5mm, BOP/SUP, BL \geq 2.5mm or BL \geq 3 threads for at least 10y	n.r.	Patient level: With periodontitis: 37.93% Without periodontitis: 10.53% Implant level: 16.94%	History of periodontitis increases the risk for peri-implantitis (OR:5.1).
24	Tenenbaum et al. 2017 ⁷⁰	France	Prospective cohort study 52 patients/108 implants university 10.8y	Mucositis: BOP, no BL PI: PD \geq 5mm, BOP, BL (Progressive BL: 4.5mm)	Patient level: 73.1%	Patient level: 15.4%	Some bacteria were associated with worsened clinical situation.

Continue

Continuation

25	Zetterqvist et al. 2010 ²⁸	Multicenter (Europe: Sweden, Italy, USA)	RCT	Mucositis: n.r.	Patient level: 1%	
			112 patients/ 304 implants after 5 y: 96 patients university 5 y	PI: PD > 5 mm, BOP, SUP, BL > 5 mm from loading	n.r.	Implant level: 0.4% After 5 y no increased risk of peri-implantitis for fully etched implants compared to hybrid-designed implants.

PD: pocket depth; BOP: bleeding on probing; SUP: suppuration; BL: bone loss; n.r.: not reported; stat. sign.: statistically significant; PU: peri-implantitis; KMW: keratinized mucosa width; OR: odds ratio; RCT: randomized controlled trial; y: years

values vary significantly between those reported on implant level (21.7%,¹³ 9.25%,²⁰ 1.1–85%,²¹ 12.8%²²) and those on patient level (19.83%,²⁰ 0–39.7%,²³ 18.5%²²). For longer evaluation periods (over 9 years of functional loading) data from a retrospective and cross-sectional analysis show a prevalence for peri-implantitis of 45% (patient level, 14.5% of these patients with moderate to severe disease²⁴ and 57% after 10 years of function.²⁵

Methodological inconsistencies and shortcomings of the reporting studies^{9,14,26} led to these significant variations of the prevalence for peri-implant diseases making thus difficult to globally estimate the real impact of peri-implant biological complications. Despite the recommendations for quality improvement in peri-implant disease research of the VIII-th EWP,⁹ only few study protocols have applied these. Since 2018, according to the new classification of periodontal diseases of the WWP 2017¹⁶ clear definitions for peri-implant health, mucositis and peri-implantitis were made and these should ease and assure a more reliable evaluation of the prevalence, extent and severity of peri-implant diseases in epidemiological studies. Nonetheless, after the search of the current review, no single study applied entirely the newly proposed definition criteria for peri-implantitis (BOP/SUP, pocket depths ≥ 6 mm, bone level ≥ 3 mm of the most coronal portion of the intraosseous part of the implant)¹⁶. Either bone loss thresholds were unclearly defined, or related to 2 mm bone loss or to implant threads, and/or lower values for included peri-implant pocket depths (*i.e.*, 4 or 5 mm) were used (Table).

Analyzing closer the current evidence, following factors may affect the reported prevalence of peri-implant diseases.

Definition of peri-implantitis

More than two decades ago, peri-implantitis has been defined as an infectious pathological condition of the peri-implant tissues.^{10,27} Following the 1st European Workshop on Periodontology (EWP) in 1993 described the term peri-implantitis in relation to inflammatory processes at osseointegrated dental implants with the clinical signs of pocket formation and bone resorption following the anticipated initial bone remodeling.¹² This definition is nowadays still correct and applicable. Nonetheless, the lack of clear thresholds to define pathological values for peri-implant pocket depths and loss of the supporting bone after functional loading led to various applications of this definition in clinical studies assessing the prevalence, incidence and extent of peri-implantitis. Therefore, in the VIIIth EWP in 2012 it was agreed that the presence of clinical inflammation together with a peri-implant bone level of 2mm from the expected level after bone remodeling should be considered as criteria for defining peri-implantitis in clinical studies.⁹ When reporting incidence and baseline radiographs are available, the bone loss cutoff is set at 1–1.5mm.⁹

Despite these guidelines, the definitions used in clinical studies were inconsistent: most studies used the same threshold for peri-implant pocket depths (>5mm), but the various levels for bone loss resulted in a large range of disease occurrence. Studies reporting low prevalences for peri-implantitis (implant level) used a high bone loss thresholds: for bone loss of 5 mm 1%,²⁸ 8.80–22.20%,²⁹ for bone loss ≥ 3 mm: 9%,³⁰ 0.37%.²⁸ On the other side, high prevalences were obtained when bone loss was set at low values (< 1.5mm) or was not mentioned: 77% (0.5 mm),³¹ 47% (0.4mm).³² Logically, different bone loss

thresholds reflect various degrees of disease severity and if these define the disease, then consecutively its prevalence is miscalculated. Thus, uniformity in the reported prevalence can be seen when studies used the same bone loss levels: for bone loss 1.5–3mm 14.5%,²⁴ 12.9%,^{25,33,34,35,36,37} 8.8%,³⁶ 7.3%,³³ 6.2%,³⁵ 14.3%.²⁹

Considering the new Classification for peri-implant conditions of the WWP 2017, reporting the prevalence and incidence for plaque-induced peri-implant diseases should be more homogenous and shall provide a realistic view of the global burden of peri-implant diseases.^{16,17,19}

Timepoint of assessment

Both peri-implant mucositis and peri-implantitis have an infectious etiology based on the accumulation of a biofilm composed of periodontal pathogens on the implant surface.^{17,38,39,40,41} It is believed that peri-implant mucositis is the precursor for peri-implantitis, however, the histopathological and clinical conditions initiating this conversion are still not elucidated.¹⁹ Since peri-implantitis represents rather a chronic form of disease implying time for the osseous destruction, it seems appropriate to report on the prevalence of peri-implantitis after sufficient time in function. Analyzing the existing reports with respect to timepoint of evaluation, it seems that prevalences of peri-implantitis do not vary strongly.

Studies evaluating the prevalence of peri-implantitis after 5 years of function and for a bone-loss threshold over 2 mm report similar values (implant level) compared to those for longer observation periods (over 9 years): at 5 years 12.9%,³⁵ 16.9%,²⁵ 9.6%,⁴² 8.80%,³⁶ 10.9%,⁴³ 1.80%,⁴⁴ at over 9 years: 9%,³⁰ 6.6%,⁴⁵ 16%–26%,³⁴ 14.5%²⁴ and 29.7%.²⁵ The differences that can be seen in the above mentioned values relate to the different thresholds for bone loss that was included in the case definition (0.5 mm vs. > 2 mm), highlighting again the importance of a consensus in the establishing a clear cutoff for peri-implant bone loss. Renvert et al.⁴⁶ reported on the prevalence of peri-implant diseases with the longest follow-up of over 20 years in function and obtained similar values to those reported in the literature for 10 years: peri-implantitis 22.1%. Thus, the present data suggest that function time has only a limited

effect on the development of peri-implantitis.^{13,14,32} Nonetheless, it seems relevant that clinical studies assessing the prevalence of peri-implantitis include cases with similar periods of function. Several studies mixed shorter with longer loading periods: 6 months–17 years,³⁷ 10–46 months,⁴⁷ 1–14 years,³³ 1–11 years,³⁶ 1–18 years,⁴⁸ which may have lead to a possible underestimation of the reported prevalence/incidence of peri-implantitis.

Level of reporting: implant vs. subject level

Assessing the global burden of peri-implant diseases is a matter of patients/humans as in any other chronic systemical diseases. When prevalences of any type of disease are reported, these refer to the number of subjects affected by that disease at that moment. Therefore, it seems quite appropriate to similarly evaluate the prevalence of peri-implant pathologies at a subject level. This was also stressed out in 2012 at the VIII-th EWP consensus workshop where the impact of peri-implant diseases on individuals should be in the focus and not that on individual implants. Research assessing the prevalence of peri-implant diseases should be thus evaluated on subject-level analysis.⁹

Several previous clinical studies reported the prevalence only on implant-level making thus difficult to estimate the global impact of the disease.^{28,49,50,51} Moreover, higher prevalences are reported on patient-level as opposed to implant-level: 14.5% vs. 8.0%,²⁴ 16.4% vs. 7.3%,³³ 2.5 vs. 0.9,⁵² 12.7% vs. 4.6,⁵³ 4.7% vs. 3.6%,⁵⁴ 25.3% vs. 16.7%.⁵⁵ However, in the past 5 years, the majority of clinical studies reporting on the prevalence of peri-implantitis applied the recommendations of the VIII-th EWP and included patient-level analyses.^{24,25,33,34,35,37,53,54,55}

Evaluated population

The majority of the studies reported prevalences for peri-implant diseases investigating patients either from university or from private clinics.^{28,31,48,56} These analyses rely however on “convenience samples” of various size bearing with it a high sensitivity for selection bias not representing the global/common implant population.^{26,57} Only few studies reported the prevalence based on random patient selection²⁴ or

based on multicenter data from subjects in private and university clinics^{24,47,58} or. The VIIIth EWP from 2012 recommended for evaluations in clinical studies of the prevalence of peri-implant diseases random patient selection from multivariate treatment environments of adequate sample sizes.^{9,26}

Various prevalences for peri-implantitis have been reported when populations with additional of conditions (*i.e.*, diabetes, rheumatoid arthritis, smokers, history of periodontitis, adherence to maintenance therapy) have been investigated to assess risk factors of developing peri-implantitis. Prevalence in patient with a *history of periodontitis* seem have a higher prevalence of the disease which remains stable over time; thus, studies evaluating the presence of peri-implantitis under 5 years of function report values of 14.3–26.1% (bone loss >2mm) or 8.9–17.4% (bone loss > 3 mm) as opposed to 6.1% or 3% in patients without residual periodontitis.²⁹ Similar values were observed also in more severe cases with bone loss > 5 mm (22.2%, after 7.9 years)⁵⁰ or > 0.2 mm annual bone loss at 8.25 y (26%).⁵⁹ Similarly, in non-smokers implant level based prevalence of peri-implantitis reached 7.44% for a functional loading period of 6 months–5 years⁶⁰ and 9% after 10 years.³⁰ Additionally, higher prevalences were reported for patients not attending a maintenance program (28.80%)⁴³ as opposed to those in regular prophylaxis (after 5 years: 10.8%, 1.8%; after 10 years: 9%).^{30,43,44} Another type of population with various reports

on the prevalence of peri-implantitis are diabetic patients. Ferreira et al.⁶⁰ reported a prevalence (patient-level) of 24% as opposed to 7% of non-diabetic patients. On the other side, Tawil et al.⁶¹ reported occurrence (4.25%) of peri-implantitis only in poor controlled diabetes (HbA1c level 7-9%). Whether these patient conditions represent risk factors for developing peri-implantitis is to be discussed in a further paper of this issue.

Implants placed in pristine vs. augmented sites

Outcome of a recent systematic review⁶² indicated that implants placed in augmented sites performed slightly less effective after a mean observation period of at least 10 years compared with implants placed in pristine bone when assessing peri-implantitis (17.8% vs. 10.3%) and implant failure rates (3.6% vs. 2.5%), respectively. Patient samples included in that systematic review,⁶² however, differed with respect to clinical characteristics such as history of treated periodontitis and materials used for augmentation procedures. Moreover, none of the studies including augmentation procedures adopted the same surgical protocol, thus enhancing heterogeneity due to sample selection. Hence, considering the lack of representation of various augmentation techniques used and of the variety of implant designs, the results of that systematic review⁶² should be interpreted with caution.

References

1. Jemt T. Implant survival in the edentulous jaw-30 years of experience. part i: a retro-prospective multivariate regression analysis of overall implant failure in 4,585 consecutively treated arches. *Int J Prosthodont.* 2018 Sep/Oct;31(5):425-35. <https://doi.org/10.11607/ijp.5875>
2. Jemt T. Implant survival in the edentulous jaw: 30 years of experience. part ii: a retro-prospective multivariate regression analysis related to treated arch and implant surface roughness. *Int J Prosthodont.* 2018 Nov/Dec;31(6):531-9. <https://doi.org/10.11607/ijp.5883>
3. Doll C, Nack C, Raguse JD, Stricker A, Duttonhoefer F, Nelson K, et al. Survival analysis of dental implants and implant-retained prostheses in oral cancer patients up to 20 years. *Clin Oral Investig.* 2015 Jul;19(6):1347-52. <https://doi.org/10.1007/s00784-014-1359-2>
4. Kreissl ME, Gerds T, Muche R, Heydecke G, Strub JR. Technical complications of implant-supported fixed partial dentures in partially edentulous cases after an average observation period of 5 years. *Clin Oral Implants Res.* 2007 Dec;18(6):720-6. <https://doi.org/10.1111/j.1600-0501.2007.01414.x>
5. Papaspyridakos P, Chen CJ, Chuang SK, Weber HP, Gallucci GO. A systematic review of biologic and technical complications with fixed implant rehabilitations for edentulous patients. *Int J Oral Maxillofac Implants.* 2012 Jan-Feb;27(1):102-10.

6. Pjetursson BE, Tan K, Lang NP, Brägger U, Egger M, Zwahlen M. A systematic review of the survival and complication rates of fixed partial dentures (FPDs) after an observation period of at least 5 years. *Clin Oral Implants Res.* 2004 Dec;15(6):625-42. <https://doi.org/10.1111/j.1600-0501.2004.01117.x>
7. Jepsen S, Berglundh T, Genco R, Aass AM, Demirel K, Derks J, et al. Primary prevention of peri-implantitis: managing peri-implant mucositis. *J Clin Periodontol.* 2015 Apr;42 Suppl 16:S152-7. <https://doi.org/10.1111/jcpe.12369>
8. Lang NP, Berglundh T; Working Group 4 of Seventh European Workshop on Periodontology. Peri-implant diseases: where are we now?—Consensus of the Seventh European Workshop on Periodontology. *J Clin Periodontol.* 2011 Mar;38 Suppl 11:178-81. <https://doi.org/10.1111/j.1600-051X.2010.01674.x>
9. Sanz M, Chapple IL. Clinical research on peri-implant diseases: consensus report of Working Group 4. *J Clin Periodontol.* 2012 Feb;39 Suppl 12:202-6. <https://doi.org/10.1111/j.1600-051X.2011.01837.x>
10. Mombelli A, Oosten MA, Schurch E Jr, Land NP. The microbiota associated with successful or failing osseointegrated titanium implants. *Oral Microbiol Immunol.* 1987 Dec;2(4):145-51. <https://doi.org/10.1111/j.1399-302X.1987.tb00298.x>
11. Zitzmann NU, Berglundh T. Definition and prevalence of peri-implant diseases. *J Clin Periodontol.* 2008 Sep;35(8 Suppl):286-91. <https://doi.org/10.1111/j.1600-051X.2008.01274.x>
12. Albrektsson TI. Consensus report of session IV. Berlin: Quintessence; 1994.
13. Derks J, Tomasi C. Peri-implant health and disease. A systematic review of current epidemiology. *J Clin Periodontol.* 2015 Apr;42 Suppl 16:S158-71. <https://doi.org/10.1111/jcpe.12334>
14. Salvi GE, Cosgarea R, Sculean A. Prevalence and Mechanisms of Peri-implant Diseases. *J Dent Res.* 2017 Jan;96(1):31-7. <https://doi.org/10.1177/0022034516667484>
15. Wan D. Dorland's illustrated medical dictionary. Philadelphia: WB Saunders; 1994.
16. Berglundh T, Armitage G, Araujo MG, Avila-Ortiz G, Blanco J, Camargo PM, et al. Peri-implant diseases and conditions: Consensus report of workgroup 4 of the 2017 World Workshop on the Classification of Periodontal and Peri-Implant Diseases and Conditions. *J Periodontol.* 2018 Jun;89 Suppl 1:S313-8. <https://doi.org/10.1002/JPER.17-0739>
17. Heitz-Mayfield LJ, Salvi GE. Peri-implant mucositis. *J Periodontol.* 2018 Jun;89 Suppl 1:S257-66. <https://doi.org/10.1002/JPER.16-0488>
18. Renvert S, Persson GR, Pirih FQ, Camargo PM. Peri-implant health, peri-implant mucositis, and peri-implantitis: case definitions and diagnostic considerations. *J Clin Periodontol.* 2018 Jun;45 Suppl 20:S278-85. <https://doi.org/10.1111/jcpe.12956>
19. Schwarz F, Derks J, Monje A, Wang HL. Peri-implantitis. *J Clin Periodontol.* 2018 Jun;45 Suppl 20:S246-66. <https://doi.org/10.1111/jcpe.12954>
20. Lee CT, Huang YW, Zhu L, Weltman R. Prevalences of peri-implantitis and peri-implant mucositis: systematic review and meta-analysis. *J Dent.* 2017 Jul;62:1-12. <https://doi.org/10.1016/j.jdent.2017.04.011>
21. Dreyer H, Grischke J, Tiede C, Eberhard J, Schweitzer A, Toikkanen SE, et al. Epidemiology and risk factors of peri-implantitis: A systematic review. *J Periodontol Res.* 2018 Oct;53(5):657-81. <https://doi.org/10.1111/jre.12562>
22. Rakic M, Galindo-Moreno P, Monje A, Radovanovic S, Wang HL, Cochran D, et al. How frequent does peri-implantitis occur? A systematic review and meta-analysis. *Clin Oral Investig.* 2018 May;22(4):1805-16. <https://doi.org/10.1007/s00784-017-2276-y>
23. Doornewaard R, Jacquet W, Cosyn J, De Bruyn H. How do peri-implant biologic parameters correspond with implant survival and peri-implantitis? A critical review. *Clin Oral Implants Res.* 2018 Oct;29 Suppl 18:100-23. <https://doi.org/10.1111/clr.13264>
24. Derks J, Schaller D, Håkansson J, Wennström JL, Tomasi C, Berglundh T. Effectiveness of Implant Therapy Analyzed in a Swedish Population: prevalence of Peri-implantitis. *J Dent Res.* 2016 Jan;95(1):43-9. <https://doi.org/10.1177/0022034515608832>
25. Meijer HJ, Raghoobar GM, de Waal YC, Vissink A. Incidence of peri-implant mucositis and peri-implantitis in edentulous patients with an implant-retained mandibular overdenture during a 10-year follow-up period. *J Clin Periodontol.* 2014 Dec;41(12):1178-83. <https://doi.org/10.1111/jcpe.12311>
26. Tomasi C, Derks J. Clinical research of peri-implant diseases—quality of reporting, case definitions and methods to study incidence, prevalence and risk factors of peri-implant diseases. *J Clin Periodontol.* 2012 Feb;39 Suppl 12:207-23. <https://doi.org/10.1111/j.1600-051X.2011.01831.x>
27. Levignac J. [Periimplantation osteolysis - periimplantosis - periimplantitis]. *Rev Fr Odontostomatol.* 1965 Oct;12(8):1251-60.
28. Zetterqvist L, Feldman S, Rotter B, Vincenzi G, Wennström JL, Chierico A, et al. A prospective, multicenter, randomized-controlled 5-year study of hybrid and fully etched implants for the incidence of peri-implantitis. *J Periodontol.* 2010 Apr;81(4):493-501. <https://doi.org/10.1902/jop.2009.090492>
29. Cho-Yan Lee J, Mattheos N, Nixon KC, Ivanovski S. Residual periodontal pockets are a risk indicator for peri-implantitis in patients treated for periodontitis. *Clin Oral Implants Res.* 2012 Mar;23(3):325-33. <https://doi.org/10.1111/j.1600-0501.2011.02264.x>
30. Frisch E, Ziebolz D, Rinke S. Long-term results of implant-supported over-dentures retained by double crowns: a practice-based retrospective study after minimally 10 years follow-up. *Clin Oral Implants Res.* 2013 Dec;24(12):1281-7. <https://doi.org/10.1111/j.1600-0501.2012.02568.x>

31. Cecchinato D, Parpaiola A, Lindhe J. Mucosal inflammation and incidence of crestal bone loss among implant patients: a 10-year study. *Clin Oral Implants Res.* 2014 Jul;25(7):791-6. <https://doi.org/10.1111/clr.12209>
32. Koldsland OC, Scheie AA, Aass AM. Prevalence of peri-implantitis related to severity of the disease with different degrees of bone loss. *J Periodontol.* 2010 Feb;81(2):231-8. <https://doi.org/10.1902/jop.2009.090269>
33. Dalago HR, Schuldt Filho G, Rodrigues MA, Renvert S, Bianchini MA. Risk indicators for Peri-implantitis. A cross-sectional study with 916 implants. *Clin Oral Implants Res.* 2017 Feb;28(2):144-50. <https://doi.org/10.1111/clr.12772>
34. Daubert DM, Weinstein BF, Bordin S, Leroux BG, Flemming TF. Prevalence and predictive factors for peri-implant disease and implant failure: a cross-sectional analysis. *J Periodontol.* 2015 Mar;86(3):337-47. <https://doi.org/10.1902/jop.2014.140438>
35. Konstantinidis IK, Kotsakis GA, Gerdes S, Walter MH. Cross-sectional study on the prevalence and risk indicators of peri-implant diseases. *Eur J Oral Implantol.* 2015;8(1):75-88.
36. Rokn A, Aslroosta H, Akbari S, Najafi H, Zayeri F, Hashemi K. Prevalence of peri-implantitis in patients not participating in well-designed supportive periodontal treatments: a cross-sectional study. *Clin Oral Implants Res.* 2017 Mar;28(3):314-9. <https://doi.org/10.1111/clr.12800>
37. Aguirre-Zorzano LA, Estefanía-Fresco R, Telletxea O, Bravo M. Prevalence of peri-implant inflammatory disease in patients with a history of periodontal disease who receive supportive periodontal therapy. *Clin Oral Implants Res.* 2015 Nov;26(11):1338-44. <https://doi.org/10.1111/clr.12462>
38. Charalampakis G, Leonhardt Å, Rabe P, Dahlén G. Clinical and microbiological characteristics of peri-implantitis cases: a retrospective multicentre study. *Clin Oral Implants Res.* 2012 Sep;23(9):1045-54. <https://doi.org/10.1111/j.1600-0501.2011.02258.x>
39. Lafaurie GI, Sabogal MA, Castillo DM, Rincón MV, Gómez LA, Lesmes YA, et al. Microbiome and Microbial Biofilm Profiles of Peri-Implantitis: A Systematic Review. *J Periodontol.* 2017 Oct;88(10):1066-89. <https://doi.org/10.1902/jop.2017.170123>
40. Persson GR, Renvert S. Cluster of bacteria associated with peri-implantitis. *Clin Implant Dent Relat Res.* 2014 Dec;16(6):783-93. <https://doi.org/10.1111/cid.12052>
41. Zitzmann NU, Berglundh T, Marinello CP, Lindhe J. Expression of endothelial adhesion molecules in the alveolar ridge mucosa, gingiva and periimplant mucosa. *J Clin Periodontol.* 2002 Jun;29(6):490-5. <https://doi.org/10.1034/j.1600-051X.2002.290603.x>
42. Brägger U, Aeschlimann S, Bürgin W, Hämmerle CH, Lang NP. Biological and technical complications and failures with fixed partial dentures (FPD) on implants and teeth after four to five years of function. *Clin Oral Implants Res.* 2001 Feb;12(1):26-34. <https://doi.org/10.1034/j.1600-0501.2001.012001026.x>
43. Costa FO, Takenaka-Martinez S, Cota LO, Ferreira SD, Silva GL, Costa JE. Peri-implant disease in subjects with and without preventive maintenance: a 5-year follow-up. *J Clin Periodontol.* 2012 Feb;39(2):173-81. <https://doi.org/10.1111/j.1600-051X.2011.01819.x>
44. Gatti C, Gatti F, Chiapasco M, Esposito M. Outcome of dental implants in partially edentulous patients with and without a history of periodontitis: a 5-year interim analysis of a cohort study. *Eur J Oral Implantol.* 2008;1(1):45-51.
45. Roos-Jansåker AM, Lindahl C, Renvert H, Renvert S. Nine- to fourteen-year follow-up of implant treatment. Part II: presence of peri-implant lesions. *J Clin Periodontol.* 2006 Apr;33(4):290-5. <https://doi.org/10.1111/j.1600-051X.2006.00906.x>
46. Renvert S, Lindahl C, Persson GR. Occurrence of cases with peri-implant mucositis or peri-implantitis in a 21-26 years follow-up study. *J Clin Periodontol.* 2018 Feb;45(2):233-40. <https://doi.org/10.1111/jcpe.12822>
47. Schwarz F, Becker K, Sahm N, Horstkemper T, Rousi K, Becker J. The prevalence of peri-implant diseases for two-piece implants with an internal tube-in-tube connection: a cross-sectional analysis of 512 implants. *Clin Oral Implants Res.* 2017 Jan;28(1):24-8. <https://doi.org/10.1111/clr.12609>
48. Mir-Mari J, Mir-Orfila P, Figueiredo R, Valmaseda-Castellón E, Gay-Escoda C. Prevalence of peri-implant diseases. A cross-sectional study based on a private practice environment. *J Clin Periodontol.* 2012 May;39(5):490-4. <https://doi.org/10.1111/j.1600-051X.2012.01872.x>
49. Kämmerer PW, Lehmann KM, Karbach J, Wegener J, Al-Nawas B, Wagner W. Prevalence of peri-implant diseases associated with a rough-surface dental implant system: 9 years after insertion. *Int J Oral Implantol Clin Res.* 2011;2:135-9. <https://doi.org/10.5005/JIP-Journals-10012-1049>
50. Pjetursson BE, Helbling C, Weber HP, Matuliene G, Salvi GE, Brägger U, et al. Peri-implantitis susceptibility as it relates to periodontal therapy and supportive care. *Clin Oral Implants Res.* 2012 Jul;23(7):888-94. <https://doi.org/10.1111/j.1600-0501.2012.02474.x>
51. Simonis P, Dufour T, Tenenbaum H. Long-term implant survival and success: a 10-16-year follow-up of non-submerged dental implants. *Clin Oral Implants Res.* 2010 Jul;21(7):772-7. <https://doi.org/10.1111/j.1600-0501.2010.01912.x>
52. Glibert M, De Bruyn H, Östman PO. Six-year radiographic, clinical, and soft tissue outcomes of immediately loaded, straight-walled, platform-switched, titanium-alloy implants with nanosurface topography. *Int J Oral Maxillofac Implants.* 2016 Jan-Feb;31(1):167-71. <https://doi.org/10.11607/jomi.4162>
53. Francetti L, Cavalli N, Taschieri S, Corbella S. Ten years follow-up retrospective study on implant survival rates and prevalence of peri-implantitis in implant-supported full-arch rehabilitations. *Clin Oral Implants Res.* 2019 Mar;30(3):252-60. <https://doi.org/10.1111/clr.13411>

54. French D, Grandin HM, Ofec R. Retrospective cohort study of 4,591 dental implants: analysis of risk indicators for bone loss and prevalence of peri-implant mucositis and peri-implantitis. *J Periodontol*. 2019 Jan;JPER.18-0236. <https://doi.org/10.1002/JPER.18-0236>
55. Katafuchi M, Weinstein BF, Leroux BG, Chen YW, Daubert DM. Restoration contour is a risk indicator for peri-implantitis: A cross-sectional radiographic analysis. *J Clin Periodontol*. 2018 Feb;45(2):225-32. <https://doi.org/10.1111/jcpe.12829>
56. Marrone A, Lasserre J, Bercy P, Brex MC. Prevalence and risk factors for peri-implant disease in Belgian adults. *Clin Oral Implants Res*. 2013 Aug;24(8):934-40. <https://doi.org/10.1111/j.1600-0501.2012.02476.x>
57. Patten SB. Selection bias in studies of major depression using clinical subjects. *J Clin Epidemiol*. 2000 Apr;53(4):351-7. [https://doi.org/10.1016/S0895-4356\(99\)00215-2](https://doi.org/10.1016/S0895-4356(99)00215-2)
58. Renvert S, Aghazadeh A, Hallström H, Persson GR. Factors related to peri-implantitis - a retrospective study. *Clin Oral Implants Res*. 2014 Apr;25(4):522-9. <https://doi.org/10.1111/clr.12208>
59. Swierkot K, Lottholz P, Flores-de-Jacoby L, Mengel R. Mucositis, peri-implantitis, implant success, and survival of implants in patients with treated generalized aggressive periodontitis: 3- to 16-year results of a prospective long-term cohort study. *J Periodontol*. 2012 Oct;83(10):1213-25. <https://doi.org/10.1902/jop.2012.110603>
60. Ferreira SD, Silva GL, Cortelli JR, Costa JE, Costa FO. Prevalence and risk variables for peri-implant disease in Brazilian subjects. *J Clin Periodontol*. 2006 Dec;33(12):929-35. <https://doi.org/10.1111/j.1600-051X.2006.01001.x>
61. Tawil G, Younan R, Azar P, Sleilati G. Conventional and advanced implant treatment in the type II diabetic patient: surgical protocol and long-term clinical results. *Int J Oral Maxillofac Implants*. 2008 Jul-Aug;23(4):744-52.
62. Salvi GE, Monje A, Tomasi C. Long-term biological complications of dental implants placed either in pristine or in augmented sites: A systematic review and meta-analysis. *Clin Oral Implants Res*. 2018 Oct;29 Suppl 16:294-310. <https://doi.org/10.1111/clr.13123>
63. Canullo L, Peñarrocha-Oltra D, Covani U, Botticelli D, Serino G, Penarrocha M. Clinical and microbiological findings in patients with peri-implantitis: a cross-sectional study. *Clin Oral Implants Res*. 2016 Mar;27(3):376-82. <https://doi.org/10.1111/clr.12557>
64. Fransson C, Lekholm U, Jemt T, Berglundh T. Prevalence of subjects with progressive bone loss at implants. *Clin Oral Implants Res*. 2005 Aug;16(4):440-6. <https://doi.org/10.1111/j.1600-0501.2005.01137.x>
65. Fransson C, Wennström J, Berglundh T. Clinical characteristics at implants with a history of progressive bone loss. *Clin Oral Implants Res*. 2008 Feb;19(2):142-7. <https://doi.org/10.1111/j.1600-0501.2007.01448.x>
66. Koldslund OC, Scheie AA, Aass AM. The association between selected risk indicators and severity of peri-implantitis using mixed model analyses. *J Clin Periodontol*. 2011 Mar;38(3):285-92. <https://doi.org/10.1111/j.1600-051X.2010.01659.x>
67. Monje A, Wang HL, Nart J. Association of preventive maintenance therapy compliance and peri-implant diseases: a cross-sectional study. *J Periodontol*. 2017 Oct;88(10):1030-41. <https://doi.org/10.1902/jop.2017.170135>
68. Papaspyridakos P, Barizan Bordin T, Kim YJ, DeFuria C, Pagni SE, Chochlidakis K, et al. Implant survival rates and biologic complications with implant-supported fixed complete dental prostheses: A retrospective study with up to 12-year follow-up. *Clin Oral Implants Res*. 2018 Aug;29(8):881-93. <https://doi.org/10.1111/clr.13340>
69. Rinke S, Ohl S, Ziebolz D, Lange K, Eickholz P. Prevalence of periimplant disease in partially edentulous patients: a practice-based cross-sectional study. *Clin Oral Implants Res*. 2011 Aug;22(8):826-33. <https://doi.org/10.1111/j.1600-0501.2010.02061.x>
70. Tenenbaum H, Bogen O, Séverac F, Elkaim R, Davideau JL, Huck O. Long-term prospective cohort study on dental implants: clinical and microbiological parameters. *Clin Oral Implants Res*. 2017 Jan;28(1):86-94. <https://doi.org/10.1111/clr.12764>